PILOT PROJECT 2: Understanding the biology of an ADCK4-NUMBL fusion in lung adenocarcinoma aggressiveness
- Institution
- PONCE SCHOOL OF MEDICINE, PR
- Principal investigator
- Harold I Saavedra
- Funding
- $145K
- Duration
- 2025–2028
Moonbase score
Still being scored
Abstract
Lung malignancies are the leading cause of cancer death. We have identified an ADCK4-NUMBL cis-SAGe fusion transcript by screening a cohort of lung adenocarcinoma patients known to lack typical oncogenic drivers. Cis-splicing between adjacent genes (cis-SAGe) is an understudied biological mechanism associated with an increase in genomic complexity. We find that the ADCK4-NUMBL fusion transcript is detectable in normal immortalized lung epithelial cells and at various levels in seven lung cancer cell lines evaluated. Likewise, measurement of the ADCK4-NUMBL Exon 14-Exon 2 transcripts in RNA derived from tumors from patients with lung adenocarcinoma revealed significant variation. A cohort of 193 lung adenocarcinoma patients was divided into high and low ADCK4-NUMBL expression groups, and overall survival comparisons were made. KaplanMeier analysis revealed that patients with high RNA expression (above the median) of ADCK4-NUMBL have diminished overall survival (Log-rank p <0.001) compared to patients with low expression. ADCK4-NUMBL levels were elevated in self-identified Black patients (p = 0.01), in smokers (p = 0.03), and in patients with KRAS mutations (p <0.04). No differences in ADCK4-NUMBL expression were observed when comparing patients by sex, age, stage, or body mass index. NUMBL immunoprecipitation, gel electrophoresis, and mass spectrometry analysis support the conclusion that the endogenous ADCK4-NUMBL transcript produces a protein product. Enforced expression of the ADCK4-NUMBL Exon 14-Exon 2 protein in A549 cells results in accelerated cell proliferation. These preliminary findings lead us to hypothesize that the ADCK4-NUMBL transcript produces an oncogenic protein that contributes significantly to lung cancer aggressiveness in a subset of lung cancer patients. In this pilot study, we propose the following exploratory aims to probe deeper into this general hypothesis and generate a strong premise for a future R01 application.
Research team
- Guillermo N Armaiz-PenaPI
- Alvaro N MonteiroPI
- Harold I SaavedraPI
LOADING MOONBASE SCORE
Questions for PONCE SCHOOL OF MEDICINE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Oregon Health & Science UniversityNot yet scored
The role of biobehavioral factors and anti-inflammatory medications on the ovarian tumor immune response
Guillermo N Armaiz-Pena · $650K · 2024–2029
- NIH · Ponce School of MedicineNot yet scored
Mental Health CPR: Transforming Cancer Survivors' Mental Health with Community Participatory Reach
Guillermo N Armaiz-Pena · $1.4M · 2023–2028
- NIH · Ponce School of MedicineNot yet scored
Targeting centrosome‐mitotic kinases as a novel therapeutic approach against breast cancers in Hispanic/Latinas.
William Douglas Cress · $1.1M · 2022–2027